VISEN Pharmaceuticals (T06) Stock Overview

An investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. More details

T06 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 79.4% below our estimate of its fair value

Revenue is forecast to grow 79.62% per year

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue (CN¥136K)

Currently unprofitable and not forecast to become profitable over the next 3 years

T06 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW479,582 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

479,582 investors already sharing narratives

View all narratives

VISEN Pharmaceuticals Competitors

Price History & Performance

Summary of share price highs, lows and changes for VISEN Pharmaceuticals
Historical stock prices
Current Share Price	HK$2.02
52 Week High	HK$2.80
52 Week Low	HK$2.02
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	T06	DE Biotechs	DE Market
7D	-3.8%	-0.1%	0.1%
1Y	n/a	11.4%	-0.5%

Return vs Industry: Insufficient data to determine how T06 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how T06 performed against the German Market.

Price Volatility

Is T06's price volatile compared to industry and market?
T06 volatility
T06 Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.7%
Market Average Movement	5.3%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: T06's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine T06's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	82	Pony Lu	www.visenpharma.com/cn

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism, which has completed phase 3 clinical trial.

VISEN Pharmaceuticals Fundamentals Summary

How do VISEN Pharmaceuticals's earnings and revenue compare to its market cap?
T06 fundamental statistics
Market cap	€230.57m
Earnings (TTM)	-€32.79m
Revenue (TTM)	€17.60k

Over9,999x

P/S Ratio

-7.0x

P/E Ratio

Is T06 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
T06 income statement (TTM)
Revenue	CN¥136.00k
Cost of Revenue	CN¥146.00k
Gross Profit	-CN¥10.00k
Other Expenses	CN¥253.41m
Earnings	-CN¥253.42m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-2.32
Gross Margin	-7.35%
Net Profit Margin	-186,339.71%
Debt/Equity Ratio	22.3%

How did T06 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/22 17:21
End of Day Share Price	2026/07/22 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VISEN Pharmaceuticals is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Zhu Chen	Citic Securities Co., Ltd.
Chu Wang	Jefferies LLC
Po Han Lin	Morgan Stanley

VISEN PharmaceuticalsDB:T06 Stock Report